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γ-secretase generates the peptides of Alzheimer’s disease, Aβ40 and Aβ42, by cleaving the amyloid 
precursor protein within its transmembrane domain. γ-secretase also cleaves numerous other 
substrates, raising concerns about γ-secretase inhibitor off-target effects. Another important 
class of drugs, γ-secretase modulators, alter the cleavage site of γ-secretase on amyloid precursor 
protein,  changing  the  Aβ42/Aβ40  ratio,  and  are  thus  a  promising  therapeutic  approach  for 
Alzheimer’s disease. However, the target for γ-secretase modulators is uncertain, with some data 
suggesting that they function on γ-secretase, whereas others support their binding to the amyloid 
precursor. In this paper we address this controversy by using a fluorescence resonance energy 
transfer-based assay to examine whether γ-secretase modulators alter Presenilin-1/γ-secretase 
conformation in intact cells in the absence of its natural substrates such as amyloid precursor 
protein and notch. We report that the γ-secretase allosteric site is located within the γ-secretase 
complex, but substrate docking is needed for γ-secretase modulators to access this site. 
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P
resenilin-1 (PS1)/γ-secretase is responsible for the final cut 
of the amyloid precursor protein (APP) to generate the Aβ 
peptide1,2. The two major Aβ species, Aβ40 and Aβ42, are pro-
duced in an approximately 9:1 ratio. The longer Aβ42 peptide is 
more prone to forming toxic oligomeric species, and is believed 
to be involved in the pathogenesis of Alzheimer’s disease (AD)3,4. 
Because γ-secretase cleaves other essential proteins (for example, 
the Notch receptor), simple γ-secretase inhibition raises concern 
for off-target effect. Another important class of drugs, γ-secretase 
modulators (GSMs), alter the cleavage site of γ-secretase on APP, 
changing the Aβ42/40 ratio5–8, and are thus a promising therapeutic 
approach for AD.
We have previously reported that alterations in the Aβ42/40 ratio 
are tightly linked to conformational changes in PS19–11. To analyse 
conformational change in PS1 in living cells, we have recently devel-
oped the G-PS1-R fluorescent probe, which has green fluorescent 
protein (GFP) at the PS1 N terminus (NT) and RFP in the large 
cytosolic-loop domain (Fig. 1a). This enables us to monitor PS1 con-
formation (that is, PS1 NT to loop proximity) by FRET/fluorescent 
lifetime imaging microscopy (FLIM). Using this probe, we demon-
strated that FRET reflects PS1 conformation, reliably predicting the 
Aβ42/40 ratio. We found that PS1 adopts a ‘closed’ conformation (that 
is, close PS1 NT-loop proximity) in response to various manipula-
tions that increase the Aβ42/40 ratio (for example, fenofibrate treat-
ment, familial Alzheimer’s disease (FAD) PS1 mutations and Pen-2 
NT modification), whereas the ‘open’ conformation (greater dis-
tance between the PS1 NT and loop) corresponds to a lower Aβ42/40 
ratio (for example, in response to ibuprofen treatment)11.
On the basis of the above findings, we postulated that GSMs 
function on a yet unidentified ‘allosteric site’ to shift PS1/γ-secretase 
conformation into either the ‘open’ or ‘closed’ state, which leads to a 
changed alignment of the γ-secretase with the APP substrate, thereby 
resulting in a decrease or increase in the Aβ42/40 ratio, respectively. 
The presence of this ‘allosteric site’ within PS1/γ-secretase itself has 
been suggested in several studies5–7. However, it has recently been 
reported that a subset of biotinylated photoactivatable forms of cer-
tain GSMs (that is, fenofibrate, flurbiprofen) could directly label the 
γ-secretase substrate, APP and to a lesser extent Notch, rather than 
the components of the γ-secretase complex itself8.
To address this controversy directly, we examined whether GSMs 
alter PS1/γ-secretase conformation in the absence of its natural sub-
strates (APP, C99, Notch∆EC) in intact and/or live cells. Treatment 
with GSMs led to a robust change in γ-secretase conformation only 
in the presence of substrates or a small helical peptide (HP) docking 
site inhibitor12. The HP shares sequence with the APP transmem-
brane domain but lacks the previously reported GSM binding site12. 
These  data  suggest  that  GSMs  affect  PS1/γ-secretase  conforma-
tion by binding to an allosteric site uncovered by occupancy of the 
enzyme’s docking site. We also directly manipulated potential sites 
of allosteric modulation of the γ-secretase complex10,13, and found 
analogous changes in the absence of APP substrate. These findings 
suggest that the γ-secretase allosteric site is located within the γ-
secretase complex itself but substrate docking is needed for GSMs 
to access this site.
Results
The effect of GSMs on PS1 conformation is substrate dependent. 
We used cells lacking APP and APLP2 (APP/APLP2 dKO cells) and 
expressing undetectable levels of endogenous Notch to dissect the 
impact of substrate expression on the action of GSMs. First, the 
proximity between GFP-PS1 NT and RFP-PS1-loop was analysed 
by  FLIM  in  either  APP/APLP2  dKO  cells  or  APP/APLP2  dKO 
cells reconstituted by stably expressing the human APP695 isoform 
(APP/APLP2 dKO + 695 cells) transfected with the G-PS1-R probe. 
We found that the GFP donor lifetime was significantly shorter in 
APP/APLP2 dKO + 695 cells, compared with that in APP/APLP2 
dKO cells (Fig. 1b), indicating closer PS1 NT-loop proximity in the 
presence of APP substrate. Transient transfection of the full-length 
(FL) human APP into APP/APLP2 dKO cells led to a similar change 
in the PS1 conformation (Supplementary Fig. S1). To further validate 
these  findings,  we  assessed  the  effect  of  immediate  γ-secretase 
substrates on PS1 conformation by transient expression of APP C99 
and Notch∆EC in APP/APLP2 dKO cells. Similar to FL APP, both 
C99 and Notch∆EC expression induced significant shortening of 
the GFP donor lifetime in the G-PS1-R probe (Fig. 1c). It has been 
shown that the PS1 protein, as it matures and trafficks through the 
secretory pathway, adopts a ring-like structure14–16 with PS1 N- and 
C-termini close enough to support FRET10. Our current findings 
suggest that substrate recruitment and/or entry into the γ-secretase 
induces PS1 conformation change by bringing PS1 NT and loop 
domains closer together.
Next, we asked whether substrate expression is required for GSMs 
to induce an allosteric conformational change in PS1. We reasoned 
that if GSMs are primarily targeting APP substrate8, they should have 
little or no effect on PS1 conformation in the absence of APP. Either 
APP/APLP2 dKO cells or APP/APLP2 dKO + 695 cells transfected 
with the G-PS1-R probe were treated with the Aβ42-raising GSM, 
fenofibrate, to test whether it can induce a ‘closed’ conformation of 
PS1. Interestingly, although fenofibrate treatment shortened the life-
time of the GFP donor in APP/APLP2 dKO + 695 cells, it failed to 
induce any conformational change of G-PS1-R in APP/APLP2 dKO 
cells (Fig. 1b). Fenofibrate treatment similarly induced a ‘closed’ PS1 
conformation in APP/APLP2 dKO cells transiently transfected with 
FL APP (Supplementary Fig. S1). This suggested that the effect of 
fenofibrate to induce the ‘closed’ conformation of PS1 is correlated 
with the presence of APP substrate. Figure 2 shows that fenofibrate 
increased the Aβ42/40 ratio (Fig. 2a) and altered G-PS1-R conforma-
tion (Fig. 2b) in a dose-dependent manner in 7W Chinese hamster 
ovary (CHO) cells stably expressing human FL APP17.
To explore whether FL APP is needed for the effect of GSMs or 
if APP C99 will suffice, APP/APLP2 dKO cells were transiently co-
transfected with C99 and the G-PS1-R probe and were treated with 
modulators of the Aβ42/40 ratio. Similar to the above observations, 
treatment of C99-expressing cells with fenofibrate also induced a 
‘closing’  of  the  PS1  conformation,  whereas  ibuprofen  treatment, 
known to lower the A42/40 ratio18, led to an ‘opening’ of the G-PS1-
R conformation, compared with vehicle-treated cells. This supports 
the idea that the presence of the immediate γ-secretase substrate is 
required for the action of these GSMs (Fig. 1c). The pseudo-colour 
FLIM images in Figure 1d show GFP lifetime distribution in APP/
APLP2 dKO cells expressing C99 and treated with GSMs. Treatment 
with  aspirin  or  naproxen,  non-steroidal  anti-inflammatory  drugs 
(NSAIDs) that do not affect the Aβ42/40 ratio18, had no effect on G-PS1-
R conformation in APP/APLP2 dKO cells expressing C99. However, 
the other two NSAIDs known to modify the Aβ42/40 ratio, flurbiprofen 
and celecoxib19, had an effect on G-PS1-R conformation, which is 
comparable to that of ibuprofen and fenofibrate, respectively (Sup-
plementary Fig. S2). Similar to C99, transfection with Notch∆EC 
facilitated the effect of fenofibrate and ibuprofen on conformational 
changes of the G-PS1-R protein in APP/APLP2 dKO cells (Fig. 1c). 
On the contrary, GSMs failed to affect G-PS1-R conformation in the 
presence of CLAC-P, a type II transmembrane protein that is not a 
γ-secretase substrate20 (Fig. 1c). This suggests that substrate binding 
to the PS1/γ-secretase is necessary for the action of GSMs.
HP  enables  GSMs  to  change  PS1  conformation.  According  to 
Kukar  et  al.,8  the  APP  transmembrane  region  Aβ29-36  (GAI-
IGLMV) is the binding site for these GSMs. To determine whether 
substrate binding of GSMs is necessary for the induction of PS1 con-
formation change, we took advantage of the previously reported HP 
γ-secretase docking-site inhibitor12, which lacks this putative GSM 
binding site as well as the APP luminal and cytoplasmic domains ARTICLE     
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(Fig. 3a). Surprisingly, both fenofibrate and ibuprofen could modu-
late PS1 conformation in APP/APLP dKO cells in the presence of HP 
(Fig. 3b). The ability of HP to inhibit APP cleavage by PS1/γ-secretase   
and APP–PS1 interaction was demonstrated by western blot and 
FLIM  experiments,  respectively  (Supplementary  Fig.  S3a,b).  To 
test whether ibuprofen and fenofibrate may affect HP binding to the   
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Figure 1 | Substrate-dependent and -independent changes of PS1 conformation. (a) schematic structure of the G-Ps1-R probe. GFP is fused to the Ps1 
n terminus (nT), and RFP is inserted into the large cytoplasmic loop between transmembrane domains 6 and 7. The red dots indicate D257 and D385 
catalytic site aspartates. (b) FLIm analysis of the Ps1 conformation in APP/APLP2 dKo cells (black bars) and in APP/APLP dKo cells reconstituted by 
stable expression of APP695 (APPdKo + 695, green bars). GFP-Ps1 (G-Ps1)-transfected cells were used as a negative control to establish GFP lifetime in 
the absence of an acceptor fluorophore, which was comparable in APP/APLP2 dKo and APPdKo + 695 cells (black and green bars, respectively). The GFP 
lifetime in G-Ps1-R-transfected cells was compared in APP/APLP dKo and APP/APLP dKo + 695 cells treated with vehicle or fenofibrate (ff) in  
three independent experiments (mean  ±  s.d.; *P < 0.001; ns, not significant; Fisher’s PsLD, AnoVA; n = 15–18 cells per condition were examined). (c) Ps1 
conformation was monitored in APP/APLP2 dKo cells co-transfected with G-Ps1-R probe and either empty vector (black bars), C99 (red bars), notch∆EC 
(blue bars) or CLAC-P (grey bars) constructs. The cells were treated with vehicle control, 100 µm fenofibrate (ff) or 400 µm ibuprofen (ibu) for 24 h. 
The graph shows mean  ±  s.d. lifetime in psec; *P < 0.05, **P < 0.001; ns, not significant; AnoVA, n = 3–5 independent experiments. on an average, 12–33 
(vehicle), 17–20 (ff) and 12–18 (ibu) cells were examined. (d) The intensity images show GFP fluorescence reflecting the expression pattern of G-Ps1-R 
probe. Pseudo-coloured FLIm images show subcellular distribution of the GFP lifetimes, with red pixels representing shorter lifetime (closer GFP-Ps1 nT 
and RFP-Ps1-loop proximity). Expression of the C99 substrate significantly increases red pixels, especially at the cell periphery. Ibuprofen reduces and 
fenofibrate increases the amount of red pixels, indicating ‘opening’ and ‘closing’ of the G-Ps1-R conformation, respectively. The cell profiles are shown by 
tracing. A colourimetric scale bar shows colour-coded fluorescence lifetime in picoseconds.ARTICLE
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initial substrate-docking site in intact cells, CHO 7W cells or primary 
neurons were treated with HP in the presence or absence of a GSM, 
and APP/γ-secretase interactions were monitored by both western 
blot and FLIM analyses. We reasoned that if a GSM affects HP bind-
ing to the initial substrate-docking site, it would interfere with the 
ability of HP to inhibit APP substrate binding to and processing by 
γ-secretase. Thus, we monitored the APP substrate binding to γ-secre-
tase by FLIM APP–PS1 proximity assay, and APP cleavage by western 
blot analysis of the APP C-terminal fragment levels. We did not detect 
any significant change in the ability of HP to bind to PS1/γ-secretase, 
and therefore to prevent APP/γ-secretase interactions after treatment 
with these GSMs (Supplementary Fig. S3c,d).
Manipulations of γ-secretase components change PS1 confor-
mation. We have previously shown that direct manipulation of   
γ-secretase components such as introduction of FAD linked muta-
tions in PS110 and modification of the Pen-2 NT13 lead to a ‘closed’ 
conformation in APP-expressing cells. We asked whether, similar to 
GSMs, these conformational changes required the binding of sub-
strate to the docking site. To test this, either G-PS1-R or G-PS1-R 
with the FAD-linked L166P mutation was transfected into APP/
APLP dKO cells and NT-loop proximity was measured by FLIM. 
The lifetime of the GFP donor at the PS1 NT was shorter in the 
presence of the L166P mutation compared with that in the wild-
type G-PS1-R (Fig. 3c). Similarly, co-transfection of G-PS1-R with 
wild-type Pen-2 or Pen-2 in which the NT is modified by addition 
of a Flag epitope tag13 caused an alteration in PS1 conformation in 
Pen-2-flag-expressing APP/APLP2 dKO cells by bringing PS1 NT 
and the loop closer together, compared with that in cells express-
ing  wild-type  Pen-2  (Fig.  3d).  Collectively,  these  results  suggest 
that direct manipulations of these γ-secretase components affect 
PS1 conformation independently of the presence of APP/APLP2   
substrates.  Of  note,  overexpression  of  wild-type  Pen-2,  together 
with G-PS1-R, in APP/APLP2 cells leads to increased GFP lifetime   
compared with that in cells transfected with G-PS1-R alone, suggest-
ing that, in the absence of APP substrate, Pen-2 expression causes 
‘opening’ of the PS1 conformation. For comparison of different PS1 
conformational states in APP/APLP2 dKO cells, we calculated the 
percentage of FRET efficiency for the G-PS1-R probe in different 
experimental conditions (Supplementary Table S1).
Discussion
Given the substrate labelling by photoactivatable GSMs demon-
strated by Kukar et al.,8 we considered three possible mechanisms 
of action of GSMs. Perhaps the most straightforward explanation 
is that the binding of GSMs to APP leads to a change in how APP 
is presented to the γ-secretase catalytic site. Indeed, during prepa-
ration of this paper, another group presented data suggesting that 
binding of GSMs to the Aβ domain could affect the APP dimeriza-
tion state, thereby altering the Aβ42/40 ratio21. Alternatively, GSM-
bound APP induces a change in PS1/γ-secretase conformation, 
which in turn alters the presentation of APP to the γ-secretase 
active site. This possibility is supported by our previous observa-
tion that the FAD-causing mutations in APP led to changes in 
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dKo cells were transfected with either wild-type G-Ps1-R probe or G-Ps1-R 
with FAD L166P mutation, and Ps1 nT (GFP) to Ps1-loop (RFP) proximity 
was analysed by FLIm (mean  ±  s.d.; *P < 0.05, AnoVA, n = 3 independent 
experiments). on an average, 18–21 cells per condition were examined. (d) 
FLIm analysis of Ps1 conformation in APP/APLP dKo cells co-transfected 
with G-Ps1-R probe, together with either wild-type Pen-2 or n-terminally 
modified Flag-Pen-2 (mean  ±  s.d.; *P < 0.05, AnoVA, n = 3 independent 
experiments). on an average, 14–16 cells per condition were examined.ARTICLE     
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PS1/γ-secretase  conformation22.  A  more  likely  scenario  is  that 
the GSM binding site is on γ-secretase, close to the PS1/substrate 
interface, and that crosslinking to APP described by Kukar et al.8 
reveals this proximity. The first and second hypotheses cannot 
clearly explain our findings that, in the absence of APP, an HP, 
which lacks the putative GSM binding site, was quite unexpect-
edly able to mediate the effects of GSMs on PS1 conformation 
(Fig. 3b). In addition, Kukar et al.8 reported that binding of GSMs 
to Notch is far less efficient than binding to APP, whereas in the 
current study fenofibrate and ibuprofen could modify PS1 con-
formation in the presence of Notch substrate, arguing against the 
‘substrate targeting’ of GSMs. The substrate targeting of GSMs 
has been recently brought into question by a study demonstrat-
ing that mutations in the proposed GSM binding site on APP did 
not change the effect of GSMs on the Aβ42/40 ratio23. Moreover, the 
specificity of GSMs binding to APP was challenged by an NMR-
based study24. Furthermore, some aggressive PS1 mutations are 
resistant to the ability of NSAIDs to reduce the Aβ42/40 ratio25. It is 
possible that as the ‘closed’ conformation of FAD-mutant PS1 is 
determined by the intrinsic molecular structure derived from its 
primary amino acid sequence, which forces PS1 into the ‘closed’ 
conformation, it may disable the access of GSMs to the allos-
teric site to a variable degree. Conversely, the Aβ42-raising APP 
mutants respond to GSMs that can reduce the Aβ42 production as 
efficiently as the wild-type APP23, supporting the idea that GSMs 
function  on  the  PS1/γ-secretase.  Accordingly,  direct  manipu-
lation of the potential GSM targets in the γ-secretase complex, 
either Pen-2 or PS1, causes conformational changes in PS1 even 
in the absence of APP/APLP2.
On the basis of our findings, we propose a model for the action of 
GSMs on PS1 conformation (Fig. 4). In this model, a hidden ‘allos-
teric’ site, presumably within the γ-secretase complex or at the PS1/
substrate interface, becomes accessible to GSMs only after binding 
of the γ-secretase substrate or HP to a ‘substrate docking site’ (first 
step). Subsequent action of GSMs on the ‘allosteric site’ induces a 
PS1 conformational change (second step), which changes its align-
ment with the APP substrate and thus the site of γ-cleavage on APP. 
This model does not rule out the possibility that some GSMs may 
initially bind to the APP substrate or even to the HP used in this 
study. In this alternative scenario, binding of the APP transmem-
brane domain to the substrate-docking site on γ-secretase, which 
‘activates’ the allosteric site, allows substrate-bound GSMs to exert 
an effect on the allosteric site located near the PS1/substrate inter-
face to induce PS1 conformational change. In either scenario, our 
data suggest that substrate docking has a key role in mediating the 
effects of GSMs on PS1 conformation in intact cells, and the mod-
ulatory effect of GSMs is implemented through the ‘allosteric site’ 
apparently located within the γ-secretase complex.
Collectively, our report demonstrates that there are substrate-
dependent  and  -independent  factors  underlying  PS1  conforma-
tional changes after. We show that the transmembrane domain of 
the γ-secretase substrate has a significant role in enabling some 
GSMs (specifically fenofibrate, celcoxib, flurbiprofen and ibuprofen, 
used in this study) to induce conformational changes in PS1. It is 
plausible that numerous environmental factors could affect either 
APP substrate or PS1/γ-secretase directly to modulate the Aβ42/40 
ratio, and lead to pathological changes associated with AD. Thus, 
further understanding of the substrate-dependent and -independ-
ent effects on PS1 conformation and the Aβ42/40 ratio is important 
for the design of therapeutic treatments.
Methods
Cell lines and pharmacological treatments. Mouse embryonal fibroblasts were 
obtained from APP/APLP2  − / −  embryos and immortalized with a lentivirus 
expressing the SV40 T antigen without antibiotic selection. Following transforma-
tion, pooled mouse embryonal fibroblasts were stored for later use or subsequently 
stably transfected with FL human APP 695 complementary DNA through lentiviral 
infection and selected with hygromycin. All the transformants were used as pooled 
cultures without clonal selection. All protocols related to the use of animals were 
previously approved by the Institutional Animal Care and Use committee to ensure 
compliance with Federal, State and local government regulations and animal 
welfare organization guidelines. CHO cells were obtained from American Type 
Culture Collection. CHO cells stably expressing wild-type human APP 751  
(7W cells) were described previously17. All cells were maintained in Opti-MEM 
(Invitrogen) supplemented with 5% fetal bovine serum. The cells were plated into 
four-chamber slides, transfected with various constructs and used for FLIM  
analyses. To evaluate the effect of GSMs on PS1 conformation, the cells were treated 
for 24 h with 100 µM fenofibrate (Sigma), 400 µM ibuprofen (Sigma), 375 µM 
fluibiprofen (Sigma), 10 µM celecoxib (Sigma), 400 µM Naproxen (Biomol) and 
500 µM Aspirin (Fluka). Ethanol or DMSO was used as a vehicle control for GSM 
experiments. To analyse the effect of fenofibrate on the Aβ42/40 ratio and G-PS1-R 
conformation, 7W cells were plated into 35 mm glass-bottomed dishes (Mat Tek) 
and treated with designated concentrations of fenofibrate for 24 h. The cells were 
subjected to FLIM assay, whereas the media were collected for human Aβ enzyme-
linked immunosorbent assay (ELISA) to determine the Aβ42/40 ratio. To compete 
out APP binding to the PS1/γ-secretase, cells were treated for 24 h with 100 nM HP 
(Boc-Val Gly Aib Val Val Ile Aib Phe Val-Aib OMe), which was designed to mimic 
a portion of the APP transmembrane domain12. To inhibit catalytic activity of the 
γ-secretase, 7W cells were treated for 24 h with either 1 µM WPE-III-31C26  
or 7.5 µM L68545827 (Sigma) transition state analogue inhibitors. Dimethyl-
sulphoxide was used as a vehicle control for the inhibitor treatments.
Constructs and transfections. The generation of G-PS1-R and PS1-loop-RFP 
constructs was previously described11. C99, an APP C-terminal fragment construct, 
containing APP signal peptide (SP) was produced as follows: SP from APP was  
cloned into NheI–HindIII sites of the pcDNA 3.1 expression vector (Invitrogen). C99  
sequence was amplified by PCR and cloned into HindIII–KpnI sites of SP-pcDNA3.1. 
The amino acids between SP and C99 were mutated into DA (Asp-Ala) by site-directed 
mutagenesis28. N-terminally truncated Notch 1 receptor construct (Notch∆EC), which 
does not require ligand binding and represents a constitutively active immediate  
substrate for the γ-secretase, was a gift from Dr R. Kopan29. Human APP 695 tagged 
with GFP at its C terminus was produced as previously described30. Pen2 construct 
tagged with Flag on its NT was a gift from Dr Selkoe (BWH, Boston, MA). Expression 
plasmid for CLAC-P was a gift from Dr Takeshi Iwatsubo (Tokyo University, Japan)20. 
The constructs were transiently transfected into cells using Lipofectamine 2000 reagent 
(Invitrogen), according to the manufacturer’s instructions.
Western blot analysis. For western blot analysis, cells plated into 35 mm cell  
culture dishes were lysed in buffer containing 1% CHAPSO (3-[(3-cholamidopropyl) 
dimethylammonio]-2-hydroxy-1-propanesulfonate), and the lysates were resolved  
on a 4–20% Tris-Glycin gel. Rabbit anti-APP C terminus (1:5,000, Sigma) and  
mouse anti-actin (1:10,000, Abcam) antibodies were used for the detection.
ELISA. The 7W cells cultured in 35 mm dishes were treated with designated 
concentrations of fenofibrate for 24 h. The conditioned medium was subjected to 
ELISA using a human β-amyloid (1–40 and 1–42) ELISA kit (WAKO), according 
to the manufacturer’s instruction.
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Figure 4 | Two-step model of the GSM action. The allosteric site responsible for Ps1 conformational change and located within the γ-secretase complex 
is hidden in the absence of APP C99/notch∆EC substrate. on binding of the substrate to the docking site, the allosteric site is ‘activated’ and becomes 
accessible for Gsms. subsequent action of Gsms on the γ-secretase allosteric site leads to ‘opening’ or ‘closing’ of Ps1 conformation.ARTICLE

nATuRE CommunICATIons | DoI: 10.1038/ncomms1129
nATuRE CommunICATIons | 1:130 | DoI: 10.1038/ncomms1129 | www.nature.com/naturecommunications
© 2010 Macmillan Publishers Limited. All rights reserved.
FLIM. The proximity between the PS1 NT and TM6-7 loop domain as an indicator  
of PS1 conformation was monitored by FLIM assay in live cells expressing  
G-PS1-R construct as previously described11. The GFP-PS1 construct, in which 
GFP donor lifetime is measured in the absence of an acceptor (FRET absent), was 
used as a negative control to determine baseline GFP lifetime. When RFP acceptor 
fluorophore is present within  < 10 nm proximity of the donor fluorophore, the GFP 
donor fluorophore lifetime shortens because of non-radiative transfer of a part 
of its emission energy to the RFP acceptor (FRET present). Thus, decrease in the 
GFP donor lifetime in the G-PS1-R construct indicates close proximity ( < 10 nm) 
between GFP fused to the PS1 NT and RFP fused into the PS1 loop domain. The 
degree of GFP lifetime shortening reflects proximity between GFP- and RFP-
  labelled epitopes, and serves as an indicator of G-PS1-R conformational changes. 
To analyse the effect of HP on APP–PS1 interactions in 7W cells, 7W cells were 
transiently co-transfected with APP-GFP- and PS1-RFP-expressing plasmids. The 
transfected cells were treated with either HP or transition state analogue inhibitors 
for 24 h and subjected to FLIM analysis.
Cells were imaged on a Zeiss LCM510 microscope equipped with a 37 °C 
heating chamber containing 5% CO2. A Chameleon pulsed laser was used to 
excite GFP donor fluorophore (two-photon excitation wavelength at 840 nm). 
Becker&Hickl FLIM hardware and software (Becker&Hickl) were used to acquire 
the donor lifetime information. Data analysis was performed using SPC Image 
(Becker&Hickl), in which donor fluorophore lifetimes are determined by fitting 
the data to one (negative control) or two (experimental conditions) exponential 
decay curves, using whole cell as a region of interest. In the two-exponential model 
of lifetime analysis, the longer (no-FRET) lifetime is ‘fixed’ as a t1 value, and the 
second, shorter lifetime reflecting the presence of FRET is calculated by the system 
as a t2 value. The t2 lifetime is used for comparisons between different experi-
mental conditions. Thus, ‘non-FRETing’ component (t1, mainly perinuclear PS1 
molecules that represent inactive PS1 holoprotein10) is excluded from the lifetime 
comparisons. The donor lifetime information could be colour coded and displayed 
in a 128×128 pixel matrix as pseudo-colour images10.
Statistical analysis. StatView for Windows, version 5.0.1 (SAS Institute) was used 
to perform statistical analysis using Fisher’s protected least significant difference 
analysis of variance (ANOVA). Samples were considered significantly different at 
P < 0.05. 
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